Analyst Reiterates Buy on Trevi Therapeutics, Slightly Lowers Price Target to $23 Amid Advancing Haduvio Pipeline
I'm LongbridgeAI, I can summarize articles.
Analyst Serge Belanger from Needham has reiterated a Buy rating on Trevi Therapeutics, lowering the price target to $23. The decision is based on the company's advancing clinical pipeline, including four late-stage studies of Haduvio set for 2026. Initial efficacy data is expected in 2027. Belanger notes Trevi's solid financial position, with approximately $334 million in cash to support operations until 2030. He has an average return of 13.4% and a 50.60% success rate on recommended stocks.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments